Priming tumors to unlock Immunotherapy's power
NCT ID NCT03519412
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a two-step approach for people with metastatic colorectal cancer that doesn't respond well to standard treatments. First, patients received a drug called temozolomide to make their tumors more genetically unstable. Then, they received the immunotherapy drug pembrolizumab (Keytruda). The goal was to see if this sequence could shrink tumors or slow their growth. The trial involved 107 participants and has been completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide and pembrolizumab
What this could lead to
If it works, this could offer a new treatment option for people with a type of colorectal cancer that usually doesn't respond to immunotherapy.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 107 participants. The approach is complex and may not work for everyone. Temozolomide can cause side effects like low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grande Ospedale Metropolitano Niguarda
Milan, Italy
-
Istituto Clinico Humanitas
Rozzano, Italy
-
Istituto Europeo di Oncologia
Milan, Italy
-
Istituto Nazionale Tumori di Milano
Milan, Italy